Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

FDA: Ranbaxy suspends atorvastatin production

Ranbaxy Pharmaceuticals has decided to stop manufacturing atorvastatin until it has thoroughly investigated the cause of quality issues and remedied the problem, the FDA announced Nov. 29.

Ranbaxy recalls atorvastatin tablets

Ranbaxy Pharmaceuticals is voluntarily recalling certain lots of its atorvastatin calcium tablets.

Sorin invests $5.4M in percutaneous mitral valve developer

Sorin Group has made a minority investment with option-to-buy in HighLife, an early-stage company focused on the development of a transcatheter mitral valve replacement system to treat patients with mitral regurgitation.

HeartSine issues Class I recall of defibrillators

HeartSine has notified customers that certain Samaritan 300/300P public access defibrillator (PAD) devices have been found to intermittently turn on and off, which may eventually deplete the battery. Thus, the company is issuing a Class I recall of the devices.

St. Jude scores EU approval of Portico transcatheter aortic heart valve

St. Jude Medical has received European CE Mark approval for its 23 mm Portico transcatheter aortic heart valve and transfemoral delivery system, which is designed for patients with severe aortic stenosis who are considered to be inoperable or high risk for conventional open-heart valve replacement surgery.

CDC: Median diabetes prevalence in U.S increases 82.2% over 15 years

The relative increase in age-adjusted prevalence of diabetes from 1995-2010 ranged from 8.5 percent in Puerto Rico to 226.7 percent in Oklahoma, with an overall median increase of 82.2 percent, according to a Centers for Disease Control and Prevention (CDC) report.

Boston Sci reaches into renal denervation market with $425M Vessix buy

Boston Scientific is extending its reach into the renal denervation market by signing a definitive agreement to acquire Vessix Vascular for $425 million.

AHA: Monoclonal antibody drug reduces LDL-C levels in statin-intolerant patients

Researchers found that a human monoclonal antibody was well-tolerated in statin-intolerant patients and reduced low density lipoprotein cholesterol (LDL-C) levels by 40.8 percent to 63 percent, depending on dosage. These findings were presented Nov. 5 at the American Heart Association scientific sessions in Los Angeles and were simultaneously published online in the Journal of the American Medical Association.

Displaying 1617 - 1624 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.